High-risk individuals for gastric cancer would be missed for surveillance without subtyping of intestinal metaplasia

被引:8
作者
Isajevs, Sergejs [1 ,2 ]
Savcenko, Selga [1 ,2 ]
Liepniece-Karele, Inta [1 ,2 ]
Piazuelo, Maria Blanca [3 ]
Kikuste, Ilze [1 ,2 ,4 ]
Tolmanis, Ivars [1 ,4 ]
Vanags, Aigars [4 ]
Gulbe, Indra [4 ]
Mezmale, Linda [1 ]
Samentaev, Darhan [5 ]
Tazedinov, Altynbek [6 ]
Samsutdinov, Ramis [5 ]
Belihina, Tatjana [5 ]
Igissinov, Nurbek [7 ]
Leja, Marcis [1 ,2 ]
机构
[1] Univ Latvia, Inst Clin & Prevent Med, Fac Med, 19 Raina Blvd, LV-1006 Riga, Latvia
[2] Riga East Univ Hosp, Riga, Latvia
[3] Vanderbilt Univ, Dept Med, Sch Med, Div Gastroenterol, Nashville, TN 37232 USA
[4] Digest Dis Ctr GASTRO, Riga, Latvia
[5] Reg Oncol Ctr, Semey, Kazakhstan
[6] Reg Diagnost Ctr, Alma Ata, Kazakhstan
[7] Cent Asian Canc Inst, Astana, Kazakhstan
关键词
Gastric cancer; OLGA; OLGIM intestinal metaplasia; Subtypes; Risk stratification; HELICOBACTER-PYLORI INFECTION; FOLLOW-UP; PRECANCEROUS LESIONS; ATROPHIC GASTRITIS; PREVALENCE; COHORT; ASSOCIATION; POPULATION; PREDICTORS; NATIONWIDE;
D O I
10.1007/s00428-021-03116-3
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
The use of Operative Link on Gastritis Assessment (OLGA) and Operative Link on Gastritis Assessment based on Intestinal Metaplasia (OLGIM) staging system is recommended for identifying subjects at risk for developing gastric cancer; usually high-risk lesions are considered only as stages III and IV. Accumulating evidence suggests that incomplete intestinal metaplasia (IM) is important in the development of gastric cancer. Our aim has been to identify the prevalence of incomplete IM in patients with low-risk OLGA/OLGIM stages among a high-risk general population. Healthy adult volunteers aged 40-64 years were invited to undergo upper endoscopy within a regional GISTAR pilot study in Kazakhstan (n = 166). Gastric lesions were staged according to OLGA/OLGIM staging system. High iron diamine-alcian blue (HID-AB) was used for subtyping IM. IM prevalence overall was 45.8%. Incomplete IM was present in 52.6% (type II in 30.3% and type III in 22.3%), whereas complete IM was found in 47.4% individuals. The prevalence of OLGIM I and II stage were 39.8 and 4.8%, respectively, whereas OLGIM III was observed in 1.2%. The prevalence of incomplete IM in patients stratified to OLGIM I was 54.5% (type II in 31.8% and type III in 22.7%). High prevalence of incomplete IM was detected not only in subjects with extensive IM, but in those stratified as at the OLGIM I stage. Without IM subtyping, patients with high risk of gastric cancer development would be missed for surveillance.
引用
收藏
页码:679 / 686
页数:8
相关论文
共 45 条
  • [31] Gastric mucosal atrophy: interobserver consistency using new criteria for classification and grading
    Rugge, M
    Correa, P
    Dixon, MF
    Fiocca, R
    Hattori, T
    Lechago, J
    Leandro, G
    Price, AB
    Sipponen, P
    Solcia, E
    Watanabe, H
    Genta, RM
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2002, 16 (07) : 1249 - 1259
  • [32] Gastritis staging in the endoscopic follow-up for the secondary prevention of gastric cancer: a 5-year prospective study of 1755 patients
    Rugge, Massimo
    Meggio, Alberto
    Pravadelli, Cecilia
    Barbareschi, Mattia
    Fassan, Matteo
    Gentilini, Maria
    Zorzi, Manuel
    De Pretis, Giovanni
    Graham, David Y.
    Genta, Robert M.
    [J]. GUT, 2019, 68 (01) : 11 - 17
  • [33] Precancerous lesions in the stomach: From biology to clinical patient management
    Rugge, Massimo
    Capelle, Lisette G.
    Cappellesso, Rocco
    Nitti, Donato
    Kuipers, Ernst J.
    [J]. BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2013, 27 (02) : 205 - 223
  • [34] Histologic Subtyping of Gastric Intestinal Metaplasia: Overview and Considerations for Clinical Practice
    Shah, Shailja C.
    Gawron, Andrew J.
    Mustafa, Reem
    Piazuelo, M. Blanca
    [J]. GASTROENTEROLOGY, 2020, 158 (03) : 745 - 750
  • [35] Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication
    Shichijo, Satoki
    Hirata, Yoshihiro
    Niikura, Ryota
    Hayakawa, Yoku
    Yamada, Atsuo
    Ushiku, Tetsuo
    Fukayama, Masashi
    Koike, Kazuhiko
    [J]. GASTROINTESTINAL ENDOSCOPY, 2016, 84 (04) : 618 - 624
  • [36] VARIANTS OF INTESTINAL METAPLASIA IN THE EVOLUTION OF CHRONIC ATROPHIC GASTRITIS AND GASTRIC-ULCER - A FOLLOW-UP-STUDY
    SILVA, S
    FILIPE, MI
    PINHO, A
    [J]. GUT, 1990, 31 (10) : 1097 - 1104
  • [37] Incidence of gastric cancer among patients with gastric precancerous lesions: observational cohort study in a low risk Western population
    Song, Huan
    Ekheden, Isabella Guncha
    Zheng, Zongli
    Ericsson, Jan
    Nyren, Olof
    Ye, Weimin
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2015, 351
  • [38] A National Study of Helicobactor pylori Infection in Gastric Biopsy Specimens
    Sonnenberg, Amnon
    Lash, Richard H.
    Genta, Robert M.
    [J]. GASTROENTEROLOGY, 2010, 139 (06) : 1894 - U157
  • [39] Type or extension of intestinal metaplasia and immature/atypical "indefinite-for-dysplasia" lesions as predictors of gastric neoplasia
    Tava, Francesca
    Luinetti, Ornbretta
    Ghigna, Maria Rosa
    Alvisi, Costanza
    Perego, Maurizio
    Trespi, Erminio
    Klersy, Catherine
    Fratti, Cesare
    Fiocca, Roberto
    Solcia, Enrico
    [J]. HUMAN PATHOLOGY, 2006, 37 (11) : 1489 - 1497
  • [40] Twelve-month endoscopic and histological analysis following proton-pump inhibitor-based triple therapy in Helicobacter pylori-positive patients with gastric ulcers
    Tulassay, Zsolt
    Stolte, Manfred
    Engstrand, Lars
    Butruk, Eugeniusz
    Malfertheiner, Peter
    Dite, Petr
    Tchernev, Konstantin
    Wong, Benjamin C. Y.
    Gottlow, Mattis
    Eklund, Stefan
    Wrangstadh, Michael
    Herszenyi, Laszlo
    Nagy, Peter
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2010, 45 (09) : 1048 - 1058